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Mammalian cells express dozens of iron-containing
proteins, yet little is known about the mechanism of
metal ligand incorporation. Human poly (rC) binding
protein 1 (PCBP1) is an iron chaperone that binds
iron and delivers it to ferritin, a cytosolic iron storage
protein. We have identified the iron-dependent prolyl
hydroxylases (PHDs) and asparaginyl hydroxylase
(FIH1) that modify hypoxia-inducible factor a (HIFa)
as targets of PCBP1. Depletion of PCBP1 or PCBP2
in cells led to loss of PHD activity, manifested by
reduced prolyl hydroxylation of HIF1a, impaired
degradation of HIF1a through the VHL/proteasome
pathway, and accumulation of active HIF1 transcrip-
tion factor. PHD activity was restored in vitro by
addition of excess Fe(II), or purified Fe-PCBP1, and
PCBP1 bound to PHD2 and FIH1 in vivo. These data
indicated that PCBP1 was required for iron incorpo-
ration into PHD and suggest a broad role for PCBP1
and 2 in delivering iron to cytosolic nonheme iron
enzymes.
INTRODUCTION
Mammalian cells express hundreds of metalloproteins. Most
contain the abundant metals iron and zinc, while others contain
various trace metals such as copper, manganese, molybdenum,
and cobalt (Waldron et al., 2009). These metals are essential
nutrients because metal cofactors activate enzymes and pro-
teins that perform critical functions in virtually every major
cellular process (Dupont et al., 2010). Several factors complicate
incorporation of the correct metal ion into a metalloprotein. First,
the binding sites for different metals within metalloproteins can
be structurally very similar, and incorporation of the noncognate
metal ion is easily achieved in vitro for many of these proteins.
Second, pools of ‘‘free’’ metal ions in cells may be vanishingly
small and the metals largely unavailable, as most zinc and
copper ions are tightly bound to cytosolic proteins (Outten and
O’Halloran, 2001). Third, redox-active metals, such as iron
and copper ions, can catalyze the production of damaging reac-Cell Mtive oxygen species, and cells must maintain tight control over
these metals in order to use them while simultaneously avoiding
their toxic effects. Fortunately, the majority of metalloproteins
receive the correct metal ion in vivo, as incorporation of the
wrong metal ion typically inactivates the protein.
Although the incorporation of the appropriate metal ion(s) into
cellular metalloproteins is a critical, essential process, the mech-
anism by which most metalloproteins receive their specific
cofactor is unknown. Some proteins rely on metallochaperones:
proteins that specifically bind metal ions and deliver them to
target enzymes and transporters through direct protein-protein
interactions (Rosenzweig, 2002). Metallochaperones delivering
nickel and copper have been described in prokaryotes and
eukaryotes, but much less is known about the delivery of iron
and zinc. Frataxin, the protein lacking in the neurodegenerative
disease Friedreich’s Ataxia, is a mitochondrial protein that is
thought to function as an iron chaperone for the assembly of
iron-sulfur clusters (Stemmler et al., 2010).
More recently, we identified poly (rC) binding protein 1
(PCBP1) as a cytosolic iron chaperone that delivers iron to ferritin
(Shi et al., 2008). In mammals, ferritin is a heteropolymer consist-
ing of 24 subunits of heavy (H) and light (L) peptides that
assemble into a hollow sphere into which iron is deposited
(Crichton, 2009; Hintze and Theil, 2006). PCBP1 binds Fe(II)
with micromolar affinity in a 3 Fe:1 PCBP1 molar ratio. PCBP1
binds ferritin in vivo and can enhance iron incorporation into
ferritin in vitro and in vivo. Mammalian cells lacking PCBP1
exhibit defects in the incorporation of iron into ferritin as well
as an increase in the labile pool of cytosolic iron and an increase
in the iron-mediated degradation of iron-regulatory protein 2.
PCBP1 (also called a-CP1 or hnRNP E1) has previously been
found to function as an RNA- and DNA- binding protein (Chaud-
hury et al., 2010; Makeyev and Liebhaber, 2002; Ostareck-
Lederer and Ostareck, 2004). PCBP1 is one member of a family
of four homologous proteins containing three heterogeneous
nuclear ribonucleoprotein K-homology (KH) domains, an ancient
and conserved RNA binding module. PCBP1, an intronless
gene, likely arose from the retrotranspositon of a splice variant
of PCBP2 mRNA, and became fixed in the genome because it
encoded a unique function not shared by the other PCBPs.
PCBP1 and 2 bind to cytosolic and viral RNAs, thereby affecting
their translation or stability. PCBPs also have a role in transcrip-
tional regulation and participate in several protein-protein
interactions.etabolism 14, 647–657, November 2, 2011 ª2011 Elsevier Inc. 647
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PCBP1 Delivers Iron to the HIF Prolyl Hydroxylase PHD2Numerous cellular proteins require iron for activity. Iron in the
form of heme and iron-sulfur clusters are cofactors for proteins
involved in a host of metabolic and regulatory functions.
Enzymes of the ‘‘nonheme’’ iron families directly coordinate
iron ions as cofactors. These families include the diiron monoox-
ygenases, such as the d-9-fatty acid desaturase and the small
subunit of ribonucleotide reductase (Shanklin et al., 2009). A
second family is the Fe(II)- and 2-oxoglutarate (2-OG)-depen-
dent dioxygenases (Kaelin and Ratcliffe, 2008; Loenarz and
Schofield, 2008; Ozer and Bruick, 2007). This family is a large,
evolutionarily conserved class of enzymes that can oxidatively
modify a variety of substrates. In mammals, four members of
this class regulate the activity of the transcription factors that
control the mammalian response to hypoxia.
Hypoxia-inducible factor (HIF) is a heterodimeric transcription
factor that binds DNA at specific sites, termed hypoxia response
elements (HREs), and activates the expression of more than 100
genes involved in the adaptation to reduced oxygen levels
(Kaelin and Ratcliffe, 2008; Loenarz and Schofield, 2008; Ozer
and Bruick, 2007). Under hypoxic conditions, the alpha subunit
(HIF1a or HIF2a) accumulates and binds to the beta subunit
(HIF1b, also called ARNT) to form the active transcription
factor. Under conditions of normoxia or hyperoxia, HIF1a is
hydroxylated on proline residues 402 and 564, which allows
the protein to be recognized by the von Hippel-Lindau tumor
suppressor protein (pVHL), thus targeting HIF1a for ubiquitin-
mediated degradation in the proteasome (Ivan et al., 2001; Jaak-
kola et al., 2001). Three HIF prolyl hydroxylases, PHD1, 2, and 3
(also called HPH-3, -2, and -1 or EGLN2, 1, and 3, respectively)
mediate the hydroxylation of proline residues on HIF1a (Bruick
and McKnight, 2001; Epstein et al., 2001), although PHD2 is
responsible for nearly all (>95%) of the activity in cultured cells
(Berra et al., 2003). HIF1a is also hydroxylated on Asn803 by
an asparaginyl hydroxylase, factor inhibiting HIF (FIH1) (Hewit-
son et al., 2002; Lando et al., 2002a). Hydroxylation of Asn803
inhibits the binding of transcriptional coactivators with HIF1a
and represents a second mechanism for inhibition of HIF activity
(Lando et al., 2002b). The activities of the HIF hydroxylases are
regulated by the availability of the cosubstrates, 2-OG and
oxygen. Because the hydroxylases exhibit changes in oxygen
binding and activity over the range of oxygen concentrations
present in tissues, these enzymes are hypothesized to function
directly as oxygen sensors.
The activities of the HIF hydroxylases may also be regulated
by the availability of iron. HIF hydroxylase activity is stimulated
by the addition of Fe(II) in vitro, and, in cultured cells, activity is
inhibited by iron chelators (Kaelin and Ratcliffe, 2008). In mice,
HIF2a accumulates in duodenal enterocytes in response to
iron deprivation, which may reflect a localized decrease in HIF
hydroxylase activity (Shah et al., 2009). Cellular factors that
control the incorporation of iron into the HIF hydroxylases are
unknown.
Here we have addressed the question of whether PCBP1, or
its paralog PCBP2, is involved in the delivery of iron to the
Fe(II)-dependent prolyl and asparaginyl hydroxylases regulating
HIF. We found that iron-deprived cells lacking PCBP1 or PCBP2
exhibited increased levels of HIF1a, whichwas due to a decrease
in prolyl hydroxylation and VHL-mediated degradation. The loss
of prolyl hydroxylase activity was traced to a decrease in iron648 Cell Metabolism 14, 647–657, November 2, 2011 ª2011 Elsevierloading of the enzyme, which could be restored with recombi-
nant PCBP1. PCBP1 physically interacted with PHD2, indicating
that PCBP1 likely acts as an iron chaperone for PHD2. Our
studies also suggest a direct role for PCBPs in the activation of
the asparaginyl hydroxylase FIH1.
RESULTS
Accumulation of Transcriptionally Active HIF1a in Cells
Lacking PCBPs
The activity of the iron-dependent PHDs is reflected in the abun-
dance of HIF1a protein. In Huh7 cells grown under normoxia,
PHDs are fully active, and HIF1a from nuclear extracts was
barely detectable (Figure 1A, left panel). Overnight treatment
(16 hr) of cells with the iron chelator desferrioxamine B (DFO)
inhibited the PHDs and led to a large accumulation of HIF1a.
We examined the effects of PCBP depletion on HIF1a levels in
the absence of DFO treatment by transfecting Huh7 cells with
small interfering RNAs (siRNAs) directed against PCBP1 and 2
and with control siRNA. Depletion of PCBP1 or PCBP1 and 2
together resulted in a 2-fold to 3-fold increase in HIF1a protein
when compared to the cells treated with control siRNA, without
a significant change in HIF1a levels in cells treated with siRNA
against PCBP2 (Figures 1A, right panel, and 1B).
We tested whether the increase in HIF1a protein was associ-
ated with an increase in HIF1a transcriptional activity. A HeLa
cell line that contains a stably integrated copy of the firefly
luciferase coding sequence under the control of the HRE exhibits
luciferase activity in proportion to the activity of theHIF transcrip-
tion factors (Tian et al., 1997). Treatment of this cell line with iron
or untreated cells exhibited very low luciferase activity, while
treatment with DFO for 16 hr led to a 27-fold increase in
luciferase activity (Figure 1C). This cell line was then depleted
of PCBP1, 2, or both PCBP1 and 2 without DFO treatment. Cells
lacking PCBP1 exhibited a 5-fold increase in luciferase activity,
while cells treated with siRNAs for both PCBP1 and 2 exhibited
a 1.6-fold increase in activity when compared to control cells.
Consistent with Figure 1A, these data indicated that, in the
absence of iron chelation, cells lacking PCBP1 exhibited both
an increase in HIF1a levels and an increase in HIF-dependent
transcription.
Increased Effects of PCBP Depletion in Mildly
Iron-Deficient Cells
While treatment of Huh7 cells with DFO for 8–14 hr markedly
inhibited cellular PHDs, brief treatments of 2–4 hr produced
a small accumulation of HIF1a, suggestive of mild iron deficiency
and partial inhibition of PHD (Figure S1C). We hypothesized
that cells depleted of PCBP might show increased sensitivity
to mild iron deficiency and briefly treated cells depleted of
PCBPs with DFO, then examined the levels of HIF1a (Figures
1D and 1E). When cells subjected to a single transfection of
PCBP siRNA were compared to cells treated with control
siRNA, cells depleted of PCBP1 exhibited a 7-fold increase in
the level of HIF1a. Cells depleted of both PCBP1 and 2 exhibited
similarly high levels of HIF1a, while cells lacking only PCBP2
exhibited a variable increase in HIF1a levels. Further depletion
of PCBP2 and PCBP1 and 2 together was achieved by two
sequential treatments with siRNA (Figures 1D and 1E, lanesInc.
Figure 1. Accumulation of HIF1a and Increased HIF Activity in Cells Depleted of PCBPs
(A–F) Elevation of HIF1a protein levels in cells lacking PCBP1 and PCBP2 (A and D). PCBP1 and PCBP2 were depleted in Huh7 cells using one (D, center panel) or
two (A and D, right panel) transfections of siRNA. Cells were then treated with no DFO or 100 mM DFO for 2 hr or 16 hr, as indicated. Nuclear extracts were
subjected to SDS-PAGE and western blotting using anti-HIF1a and anti-CREB as a loading control (A and D). HIF1a blots were quantitated and expressed as
a percentage of control-treated cells, ± SEM (B and E). Increased HIF1a transcriptional activity after depletion of PCBP1 (C). A HeLa cell line containing 3XHRE
upstream of a luciferase reporter gene was treated with 20 mMFeCl3 or 100 mMDFO, or depleted of PCBP1, PCBP2, or both in the absence of DFO. After 3 days,
cells were harvested and lysed, and luciferase activity was measured. The experiment was replicated thrice, error bars indicate SEM. * indicates p < 0.05.
Confirmation of PCBP1 and PCBP2 depletion by siRNA (F). Cytoplasmic extracts from cells in (A) were subjected to SDS-PAGE and western blotting using anti-
PCBP1 and anti-PCBP2. Membranes were reprobed with mouse anti-actin. Molecular weight standards are in kDa. See also Figure S1.
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PCBP1 Delivers Iron to the HIF Prolyl Hydroxylase PHD2marked ‘‘x2’’), which resulted in 9-fold increases in HIF1a levels.
We measured the effects of siRNA treatment on PCBPs by
western blotting and by quantitative real-time PCR, and
confirmed that our siRNA transfections produced depletion of
PCBP1 and 2 in Huh7 cells, although simultaneous depletion
of PCBP1 and 2 was less efficient than depleting them individu-
ally (Figures 1F, S1A, and S1B). To rule out off-target effects of
the siRNAs, we transfected Huh7 cells with alternative siRNAs
directed against other regions of the PCBP mRNAs and found
that these siRNAs also increased HIF1a (Figures S1E and S1F).
Although plasmid transfection efficiency of cells previously
treated with siRNA was low, the effects of PCBP1 depletion
could be partially rescued by expression of a mutant PCBP1
not targeted by the siRNA (Figure S1D).
Increased Half-Life of HIF1a in PCBP-Depleted Cells
The elevated levels of HIF1a in cells lacking PCBPs could be due
to either an increase in HIF1a gene expression or a decreased
rate of HIF1a protein degradation. We examined the levels of
HIF1a mRNA in cells depleted of PCBPs using real-time PCR
(Figure 2A). Changes in HIF1a mRNA levels in PCBP-depleted
cells were small and did not account for the observed changes
in protein levels. We next examined the half-life of HIF1a proteinCell Min Huh7 cells depleted of PCBP1 and 2 versus control cells. Cells
were treated with DFO for 2 hr, cycloheximide was added to
block new protein synthesis, cells were collected at intervals,
and nuclear extracts were examined by western blotting (Fig-
ure 2B). HIF1a protein levels were quantitated and the half-life
was calculated (Figure 2C). Consistent with previous reports,
HIF1a was rapidly degraded in control cells (t1/2 = 8 min), while
HIF1a exhibited much greater stability in cells depleted of
PCBP1 and 2 (t1/2 = 50 min), although the presence of DFO
during the cycloheximide incubation may also have contributed
to the stability of HIF1a. These data indicated that the accumu-
lation of HIF1a in cells depleted of PCBP1 was due to impaired
degradation of the protein.
Reduced Hydroxylation of HIF1a in Cells Lacking PCBPs
VHL-mediated degradation of HIF1a is dependent on the
hydroxylation of proline residues 402 and 564 on the oxygen-
dependent degradation domain of HIF1a (Ivan et al., 2001; Jaak-
kola et al., 2001). Cells lacking PCBPs may exhibit impaired
degradation of HIF1a because of impaired hydroxylation of
these proline residues; therefore, we measured the hydroxyl-
ation of Pro564 in A549 cells lacking PCBPs. A549 cells
were selected because they expressed higher levels of PHD2etabolism 14, 647–657, November 2, 2011 ª2011 Elsevier Inc. 649
Figure 2. Increase in HIF1a Half-Life in Cells Lacking PCBPs
(A) Lack of change in HIF1a mRNA levels in cells depleted of PCBPs. Huh7
cells were depleted of PCBP1, PCBP2, or both, untreated or treated with DFO
for 2 hr. HIF1a mRNA levels were measured by real-time PCR and presented
as a percentage of actin. Samples were analyzed in triplicate, and the
experiment was repeated thrice.
(B and C) Increase in HIF1a half-life in cells depleted of PCBPs. Huh7 cells
were depleted of both PCBP1 and 2, then treated with 25 mM DFO for 2 hr.
Cycloheximide was added, and the cells were lysed at indicated times. HIF1a
and CREBwere detected as in Figure 1B. Blots were quantitated, HIF1a levels
were normalized to CREB and plotted as a percentage of T = 0 levels (C). Error
bars indicate SEM.
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PCBP1 Delivers Iron to the HIF Prolyl Hydroxylase PHD2mRNA than Huh7 cells (see Figure 4A) andHIF1a-OHwas readily
detectable. A549 cells were similar to Huh7 cells in that transfec-
tions of siRNA for PCBP1, 2, and PCBP1 and 2 together also
produced markedly elevated levels of HIF1a in the presence of
DFO (Figure S2A). Depletion of PCBPs in A549 cells was also
efficient, although again simultaneous depletion of PCBP1 and650 Cell Metabolism 14, 647–657, November 2, 2011 ª2011 Elsevier2 was less efficient (Figures 3D, S2C, and S2D). We measured
hydroxylation of Pro564 by blocking proteasome-mediated
degradation with the inhibitor MG132 and detecting hydroxyl-
ated HIF1a using an antibody that specifically recognizes the
hydroxylated form (HIF1a-OH). Brief treatment of A549 cells
with 25 mM DFO did not change HIF1a-OH levels (Figure S2B),
and DFO (25 mM) was therefore included in experiments
measuring HIF1a-OH levels. Nuclear extracts were probed for
HIF1a-OH, total HIF1a, and CREB (Figures 3A and 3B).
HIF1a-OHwas readily detected in cells treated with no or control
siRNA, while cells depleted of PCBP1 exhibited dramatically
reduced levels of HIF1a-OH and cells lacking PCBP2 or
PCBP1 and 2 exhibited moderately reduced HIF1a-OH. The
specificity of the antibody for HIF1a-OH was demonstrated by
the absence of signal in untreated cells (MG132), which also
had no detectable HIF1a, and the absence of signal in cells
treated for 16 hr with DFO alone (+DFO), which had abundant
HIF1a. Although treatment withMG132 inhibited the degradation
of HIF1a in all conditions, cells depleted of PCBP1 exhibited
a higher level of total HIF1a. Despite the higher level of total
HIF1a, the decrease in HIF1a-OH was still detected, confirming
that depletion of PCBPs was associated with a loss of HIF1a
prolyl hydroxylation.
The activity of the HIF PHDs can be measured in vitro using an
assay that relies on the specific interaction of pVHL with a
HIF1a-derived peptide containing hydroxyproline 564, but not
with a peptide containing an unmodified proline (Aprelikova
et al., 2009; Tuckerman et al., 2004). We used HEK293T cell
lysates containing PHD to hydroxylate a HIF1a synthetic peptide
corresponding to residues 556–574, which had been bound to
magnetic beads. VHL protein was incubated with the peptide,
and the amount of pVHL captured was measured by western
blotting. HEK293T cells were selected because they expressed
more PHD2 than Huh7 cells, and depletion of PCBPs was very
efficient with two sequential transfections of siRNAs (Figures
3D and S2F). Cells were treated with siRNAs for PCBP1 and 2
and control siRNA, briefly treated with DFO, then lysed and
assayed for PHD activity by the pVHL capture method (Figures
3C andS2E). Cells transfectedwith no or control siRNA exhibited
readily detectable PHD activity, while cells lacking PCBP1 and 2,
individually or in combination, exhibited much lower levels of
activity (38%–13% of Control). The specificity of the hydroxyl-
ated peptide for pVHL capture was confirmed using a hydroxyl-
ated synthetic peptide as a positive control (Peptide-OH) and
lysate from cells treated overnight with DFO as a negative
control (+DFO). HEK293T cells lacking either PCBP1, 2, or
PCBP1 and 2 exhibited similar losses of PHD activity. Consistent
with this observation, the increase in the total amount of HIF1a
in HEK293T cells lacking PCBP1 and/or 2 was also similar
(Figure 3C).
Reduced Metallation of PHD2 in Cells Lacking PCBPs
The reduced hydroxylation of HIF1a in cells lacking PCBPs could
be explained by reduced levels of PHD mRNA or protein or by
reduced specific activity of the enzyme. We measured mRNA
levels of PHD2 by real-time PCR and found only small differ-
ences (less than 2-fold) between control cells and cells lacking
PCBPs in Huh7, A549, or HEK293T cell lines (Figure 4A). PHD2
protein levels did not significantly change in Huh7, HEK293,Inc.
Figure 3. Impaired HIF1a Hydroxylation and VHL Binding after Depletion of PCBPs
(A) Decrease in hydroxylated HIF1a after depletion of PCBPs. A549 cells were depleted of PCBP1, PCBP2, or both, then treated with MG132 and 25 mMDFO for
2 hr. Nuclear extracts were analyzed by western blotting with anti-HIF1a-OH, anti-HIF1a, and anti-CREB. Untreated cells (MG132) and cells treated with DFO
overnight were used as controls.
(B) Quantitation of HIF1a-OH levels in (A). Error bars indicate SEM.
(C) Decrease in pVHL binding to hydroxylated HIF1a after depletion of PCBPs. HEK293T cells depleted of PCBP1, PCBP2, or both were treated with 25 mMDFO,
and lysates were added to immobilized HIF1a peptide containing proline 564. Peptides were washed, and HA-pVHL was allowed to bind to the HIF1a
peptide. Bound HA-pVHL was measured by western blotting using anti-HA. Hydroxylated synthetic HIF1a peptide (Peptide-OH) was the positive control, and
cells treated overnight with DFO (+DFO) were the negative control. Nuclear extracts of cells depleted of PCBPs were probed for HIF1a and CREB by western
blotting.
(D) Confirmation of PCBP depletion by siRNA. A549 cells or HEK293T cells treated with siRNA were subjected to SDS-PAGE and western blotting using anti-
PCBP1 and anti-PCBP2, then reprobed for actin. HEK293T cells were sequentially transfected to deplete PCBP1 and PCBP2. See also Figure S2.
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PCBP1 Delivers Iron to the HIF Prolyl Hydroxylase PHD2and A549 cells after depletion of PCBPs (Figures 4B, 4C, and
5A). These data suggested that depletion of PCBPs reduced
the specific activity of PHD2 rather than affecting protein levels.
The activity of PHD2 is dependent on the incorporation of iron
into the enzyme. Therefore, we measured the amount of iron
bound to PHD2 from cells labeled in vivo with [55Fe]. HEK293T
cells were depleted of PCBPs, then transiently transfected to
overexpress a FLAG-epitope-tagged version of PHD2, and
labeled with [55Fe] in the absence of DFO. PHD2 with its bound
iron was recovered by immunoprecipitation and measured by
scintillation counting (Figure 4C). The amount of iron bound to
PHD2 was reduced by 78%, 62%, and 73%, respectively, in
cells lacking PCBP1, PCBP2, or PCBP1 and 2. There was no
difference in the amount of PHD2 protein immunoprecipitated
(Figure 4C, top panel). These data suggested that the loss of
PHD activity in cells lacking PCBPs was due to a failure to incor-
porate the Fe(II) cofactor.Cell MRestoration of PHD Activity with Iron or Purified PCBP1
We employed a more quantitative assay to further characterize
the loss of PHD activity in cells lacking PCBPswithout DFO treat-
ment. Peptides corresponding to residues 556–574 of HIF1a
were immobilized, then lysates from A549 cells depleted of
PCBPs were incubated with the peptides in the presence of
2-OG and ascorbate. The amount of hydroxylation of Pro564
was measured using an antibody that specifically recognized
Hydroxypro564 in the HIF1a-derived peptide. When the
hydroxylase assay included a low concentration of Fe(II) that
partially activated PHD, robust activity was detected in control
lysates, and essentially no activity was detected in lysates
from cells treated overnight with DFO (Figure 5A). Lysates from
cells depleted of PCBP1, 2, and PCBP1 and 2, but not treated
with DFO, exhibited a 67%–71% reduction in PHD activity, con-
firming that PCBPs were required for full PHD activity in cells in
the absence of DFO treatment.etabolism 14, 647–657, November 2, 2011 ª2011 Elsevier Inc. 651
Figure 4. Decrease in PHD2 Metallation after Depletion of PCBPs
(A) Lack of change in PHD2 transcript levels after depletion of PCBPs. PCBP1,
PCBP2, or both were depleted from Huh7, A549, and HEK293T cells. PHD2
mRNA levels weremeasured by real-time PCR and expressed as a percentage
of actin. Error bars indicate SEM.
(B) Lack of change in PHD2 protein levels after depletion of PCBPs. PHD2 was
detected in Huh7 whole-cell lysates by western blotting. The blot was re-
probed for actin.
(C) Less iron in immunoprecipitated PHD2 after depletion of PCBPs. PCBP1,
PCBP2, or both were depleted from HEK293T cells, then cells were transiently
transfected with p3xFLAG-CMV-PHD2 to overexpress PHD2. Cells were
labeled with 55Fe, then PHD2 was detected by western blotting, or PHD2 with
its iron ligands was immunoprecipitated using anti-FLAG. Immune complexes
were subjected to scintillation counting, and the retained 55Fe was expressed
as a percentage of the 55Fe from control lysates. Nonspecific 55Fe binding was
measured using IPs frommock-transfected cells (average 19% of control) and
subtracted. The experiment was replicated three times. Error bars indicate
SEM, * indicates p < 0.05. See also Figure S3.
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PCBP1 Delivers Iron to the HIF Prolyl Hydroxylase PHD2PHD2 that lacks the iron cofactor can be activated in vitro with
high concentrations of Fe(II) (Figure S4). We tested whether PHD
activity could be restored by treating the PCBP lysates with Fe(II)
in vitro. Lysates from control cells exhibited full PHD activity
when assayed with or without exogenous iron (Figure 5B), sug-
gesting that the PHD from these cells was fully metallated. In
contrast, lysates from cells depleted of PCBP1 and PCBP1
and 2 exhibited virtually no PHD activity in the absence of exog-
enous iron, but were restored to nearly full activity upon addition
of exogenous iron. These data suggested that the loss of PHD
activity could be fully explained by the absence of the Fe(II)652 Cell Metabolism 14, 647–657, November 2, 2011 ª2011 Elseviercofactor from the enzyme in the PCBP-depleted lysates. We
next tested whether addition of purified, iron-loaded PCBP1
could restore PHD activity. Purified recombinant PCBP1 (P1)
was incubated anaerobically with Fe(II) and added to lysates
from cells depleted of PCBPs. The lysates were then assayed
for PHD activity (Figure 5C). Iron-loaded bovine serum albumin
(BSA) and unliganded Fe(II) were used as controls, and the final
concentration of iron (10 mM) was the same for all samples.
Purified, iron-loaded PCBP1 was able to restore PHD activity
to near control levels in lysates from cells lacking PCBP1 and
to partially restore activity in lysates from cells lacking PCBP1
and 2. In contrast, addition of iron-loaded PCBP1 to lysates
from cells lacking PCBP2was nomore effective than iron-loaded
albumin or iron alone in restoring PHD activity. These data indi-
cated that iron-loaded PCBP1 could restore PHD activity
in vitro to cells lacking PCBP1, but not to cells lacking only
PCBP2. This finding suggested that PCBP1 and 2 had nonredun-
dant functions and may cooperate in the delivery of iron to PHD.
In Vivo Interactions between PCBP1 and PHD2
PCBP1 directly binds to ferritin in the process of delivering iron
for mineralization, and, in yeast cells, this interaction is depen-
dent on the presence of iron (Shi et al., 2008). We examined
the in vivo binding of PCBP1 to PHD2 in HEK293T cells by testing
for the presence of PHD2 in immune complexes precipitated
using antibodies against PCBP1 (Figure 6A). PHD2 was readily
detected in immune complexes obtained after immunoprecipita-
tion of PCBP1, and no PCBP1 or PHD2 was detected in immu-
noprecipitates using nonspecific IgY as a control antibody. The
effects of iron manipulation on PHD2 binding to PCBP1 were
small and not consistently detected. Iron manipulation had no
effect on the total levels of PHD2 or PCBP1 in the whole-cell
lysates. These data indicated a physical interaction between
PCBP1 and PHD2.
Our data suggested that both PCBP1 and 2 were involved in
the delivery of iron to PHDs, and that their functions were not
redundant. To determine whether PCBP1 and 2 physically inter-
acted, we again immunoprecipitated PCBP1 from HEK293T
cells that had been treated with iron or DFO and tested for the
presence of PCBP2 in the immune complexes (Figure 6B).
PCBP2was detected in precipitates of PCBP1, but not in control
precipitates using nonspecific IgY, demonstrating that at least
a portion of PCBP1 and PCBP2 are bound together as a complex
in vivo.
Genetic and Physical Interactions of PCBP1 with FIH1
FIH1 is an asparaginyl hydroxylase of the same Fe- and 2-OG-
dependent dioxygenase family as the PHDs, and we questioned
whether FIH1, similarly to PHD, also required PCBPs for Fe-
dependent activation. FIH1 hydroxylates a conserved aspara-
gine residue in the carboxyl-terminal transactivation domains
(CADs) of HIF1a and HIF2a (Lando et al., 2002a; Lando et al.,
2002b). This modification does not lead to degradation of the
CADs, but instead prevents the association of transcriptional
coactivators with HIF, thereby blocking the activity of the HIFa
CADs. Fusion of the CADs to the Gal4 DNA-binding domain
(GalDBD) permits the measurement of FIH1 hydroxylase activity
through the capacity of FIH1 to inhibit the GalDBD/HIF2a CAD-
dependent transcription of a Gal-responsive luciferase reporter.Inc.
Figure 5. Requirement of PCBPs for Iron-Dependent PHD Activity
(A) Decrease in PHD activity after depletion of PCBPs. A549 cells were
depleted of PCBP1 and PCBP2 by siRNA. Cells were lysed and assayed for
PHD protein (upper panels) and activity in the presence of 10 mM Fe(II).
(B) Increased PHD activity after addition of exogenous iron in lysates depleted
of PCBPs. PHD2 activity was measured as in (A) in assays containing the
indicated concentrations of iron.
(C) Restoration of PHD activity upon addition of iron-loaded PCBP1 protein to
PCBP1-depleted lysates. PHD activity measured as in (A). Purified recombi-
nant PCBP1 and BSA were loaded with Fe(II) and added to lysates prior to
measurement of PHD activity. Unliganded Fe(II) was used as an additional
control, and all assays contained 10 mM Fe as a final concentration. Activity
Figure 6. Physical Interaction of PCBP1 with PHD2
(A) Coimmunoprecipitation of endogenous PHD2 with PCBP1. HEK293T cells
were treated for 16 hr with 20 mM FeCl3 or 100 mM DFO. PCBP1 was immu-
noprecipitated using anti-PCBP1 or bulk IgY as a negative control. Panels on
right, immune complexes analyzed by western blotting for PHD2 and PCBP1.
Panels on left, western blots of whole-cell lysates before immunoprecipitation.
(B) Coimmunoprecipitation of PCBP2 with PCBP1. Cell treatment and immu-
noprecipitations were carried out as in (A), then immune complexes were
analyzed for PCBP2 and PCBP1.
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Cell MHEK293 cells were depleted of PCBPs, then cotransfected with
plasmids expressing GalDBD/HIF2a CAD, wild-type FIH1, and
a luciferase reporter under the control of a Gal4-responsive
promoter (5XGRE) (Figure 7A). Mutation of Asn851 to Ala in
HIF2a blocks hydroxylation of the Asn residue by FIH1, resulting
in constitutive activation of the HIF2a CAD. Therefore, a plasmid
containing the Asn851Ala substitution was also transfected.
Cells were not treated with DFO. In cells treated with control
siRNA, FIH1 was fully active, and luciferase activity was very
low (Figure 7B). In contrast, control cells expressing the
Asn851Ala CAD exhibited 10-fold higher luciferase activity. Cells
depleted of PCBP1 exhibited a 5-fold increase in luciferase
activity when compared to the control, and cells depleted of
PCBP1 and 2 exhibited a 3-fold increase in activity. As with
PHD2, depletion of PCBPs had no effect on FIH1 protein levels
(Figure 7C) and depletion of PCBPs by siRNA was confirmed
(Figure S5A). Similar to Figures 1A and 1C, these data suggested
that cells lacking PCBP1 had reduced FIH1 activity even without
treatment with DFO.
We tested whether FIH1 was bound to PCBP1 in HEK293
cells overexpressing FIH1 by immunoprecipitating endogenous
PCBP1 and examining immune complexes for coprecipitation
of FIH1 (Figures 7D and S5D). Similar to PHD2, FIH1 was detect-
able in immune complexes containing PCBP1, but not in control
IgY immunoprecipitations. Unlike PHD2, only immune com-
plexes from cells treated with iron contained significant copreci-
pitated FIH1. The migration of FIH1 as a doublet was frequentlywas expressed as luminescence units. Assays were performed in triplicate,
experiments were replicated four or more times. Error bars represent SEM.
See also Figure S4.
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Figure 7. Genetic and Physical Interactions of PCBP1 with FIH1
(A and B) Loss of FIH1 activity in cells lacking PCBP1. HEK293 cells were
depleted of PCBP1 and 2 with siRNA, then cotransfected with plasmids
encoding the GalDBD/HIF2a CAD or the Asn851Ala mutant CAD, Gal4-
responsive luciferase reporter, control renilla luciferase, and FIH1. Normalized
luciferase activity was expressed as a fold increase over the activity of control
siRNA treated cells. Data are the average of three transfections. Error bars
indicate SEM.
(C) Lysates from (A) were subjected to western blotting for FIH1 and reprobed
for actin.
(D) Coimmunoprecipitation of FIH1 with PCBP1. HEK293T cells transiently
expressing FIH1-myc-HisA (pFIH1) or untransfected cells (pFIH1) were
treated for 2 hr with iron and DFO, then PCBP1 was immunoprecipitated as in
Figure 6. Whole-cell lysates and immune complexes were blotted for FIH1 and
PCBP1. See also Figure S5.
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(Figure S5C). Coimmunoprecipitation of endogenous FIH1 with
PCBP1 was also detected in cells treated with iron (Figures 7D
and S5D, right panels, ‘‘pFIH1’’). These data suggested that
PCBP1 also acted as an iron chaperone for FIH1.
DISCUSSION
Although most nonheme iron enzymes receive their metal
cofactor through an unknown mechanism, our studies indicated
that PHDs and FIH1, the prolyl and asparagyl hydroxylases that
modify HIF1a, depend on members of the PCBP family of iron
chaperones/RNA-binding proteins to incorporate Fe(II) into their
active sites, especially in cells briefly exposed to iron limitation.
Cells lacking PCBP1 or 2 exhibited reduced PHD activity, which
resulted in less prolyl hydroxylation of HIF1a, less degradation of
HIF1a through the pVHL-proteasome pathway, and accumula-
tion of HIF1a protein. Because the loss of PHD activity was
associated with a loss of the iron cofactor, PCBP1 must be
involved in the metallation of PHD. Previously, we have shown
that depletion of PCBP1 in Huh7 cells does not result in a loss
of iron uptake activity and is associated with an increase in the654 Cell Metabolism 14, 647–657, November 2, 2011 ª2011 Elsevierlabile iron pool (Shi et al., 2008); therefore, cellular iron for metal-
lation of PHD must be present. We found that iron-loaded
PCBP1 specifically restored activity to inactive PHD in vitro
and that PCBP1 and PHD2 physically interacted in vivo by coim-
munoprecipitation. Thus, we propose that PCBP1 is an iron
chaperone for PHD as well as for ferritin.
We have previously shown that expression of PCBP2 in yeast
cells containing human ferritin activates the iron deficiency
response of yeast, indicating that PCBP2 can disrupt iron
homeostasis in yeast (Shi et al., 2008). Preliminary data indicate
that PCBP2 can bind both iron and ferritin, suggesting that
PCBP2 can also function as an iron chaperone (A.N., T.L.S.,
and C.C.P., unpublished data). Here, we show that cells lacking
PCBP2 also exhibit loss of PHD activity and accumulation of
HIF1a, indicating that PCBP2 is also an iron chaperone for
PHDs. The loss of FIH1 activity in cells lacking PCBP1 and the
binding of PCBP1 to FIH1 in vivo suggest that PCBP1 acts as
an iron chaperone for this second type of Fe- and 2-OG-depen-
dent oxygenase. The role of PCBP2 in the activation of FIH1 is
not yet clear.
In these studies, PCBP1 and 2 were required in cultured cells
for hydroxylation and degradation of HIF1a, but the effects were
much greater in cells transiently exposed to iron limitation. In the
absence of DFO, the effect of PCBP1 depletion on HIF1a degra-
dation was reproducible but small, and no effect of PCBP2
depletion was observed. In contrast, in vitro measurement of
PHD activity in lysates from A549 cells not treated with DFO
indicated that depletion of PCBP1 or 2 resulted in a dramatic
decrease in activity. There are multiple possible explanations
for these results: (1) When iron is present in abundance, as it
is in cell culture media, somemetallation of PHDs could proceed
in a PCBP-independent manner; (2) PHD activity may be present
in excess in vivo, and large decreases in PHD activity may be
required before HIF1a hydroxylation decreases and HIF1a accu-
mulation occurs; (3) PCBPsmay be required for the remetallation
of PHDs when the active site iron is lost, and iron limitation with
DFO could accelerate the turnover of iron in PHD active sites.
The sensitivity of PHDs to DFO treatment in vivo would suggest
that the active site iron is readily exchangeable with available
cytosolic iron pools. The loss of PHD activity in lysates lacking
PCBP1 or 2 may reflect a role for PCBPs in maintaining iron in
the active site in vitro, as well.
Our data do not suggest, however, that PCBP1 and 2 can
functionally substitute for each other. Cells lacking PCBP1 or 2
contain wild-type levels of the other paralog. Furthermore, while
addition of purified, iron-loaded PCBP1 to lysates lacking
PCBP1 fully restored PHD activity, addition of PCBP1 did not
restore activity to lysates lacking only PCBP2. PCBP1 and 2
may function as a hetero-oligomeric complex to deliver iron to
targets such as ferritin and PHD. PCBP1 and 2 bind to each other
when in complex with mRNA (Makeyev and Liebhaber, 2002),
and we have confirmed this interaction. Our data suggest
a model in which PCBP1, in complex with PCBP2 or another
PCBP family member, binds iron and interacts with target
nonheme iron enzymes to donate metal to the active site. The
differences in HIF1a accumulation that occurred with depletion
of PCBP1 versus 2 may reflect the activity of PCBP1 in complex
with residual PCBP2 or with PCBP3 or PCBP4, which are
expressed at low levels in cells.Inc.
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from PCBPs. Ferritin and the 2-OG dependent hydroxylases
are structurally dissimilar, but have certain characteristics in
common that may point to mechanisms of iron donation. Both
ferritin and PHD2 can bind iron after folding into their native
conformations. Thus, PCBPs could interact with these targets
posttranslationally to donate iron. The H-chain of ferritin cata-
lyzes the oxidation of Fe(II) to Fe(III) for ferritin core mineraliza-
tion, and the ferroxidase center structurally and mechanistically
resembles the catalytic centers of the oxo-bridged diiron family
of monooxygenases (Crichton, 2009; Hintze and Theil, 2006).
However, PCBP1 likely does not provide iron directly to the
ferroxidase sites of ferritin, as these sites are located on the
interior surface of the ferritin sphere. Iron ions gain access to
the ferroxidase sites through pores lined with hydrophilic
residues. PCBP1 could donate Fe(II) to the His, Asp, and Glu
residues that line these funnel-shaped channels. The active
site of PHD2 and other enzymes of this class is solvent-exposed
and coordinates a single Fe(II) through a His-Xaa-Asp/Glu-
Xaa(n)-His triad located deep in the active site pocket (Loenarz
and Schofield, 2008; Ozer and Bruick, 2007). Thus, the iron
ligands and the coordination environment in these two enzymes
are similar.
Given that PCBP1 serves as an iron chaperone for these two
diverse target enzymes, we suggest that it is highly likely that
other enzymes of the Fe(II)- and 2-OG oxygenase class will
require PCBPs for metallation. Sequence analysis of the human
genome indicates the presence of more than 60 enzymes of this
class, many of which have not been functionally characterized,
but are predicted to oxidatively modify a broad range of
substrates (Loenarz and Schofield, 2008; Ozer and Bruick,
2007). In addition to its role in HIF regulation, FIH functions in
mice as a regulator of metabolism, likely by hydroxylating aspar-
agine residues on proteins other than HIF (Zhang et al., 2010).
This class also includes the collagen prolyl and lysyl hydroxy-
lases, mutations in which cause connective tissue diseases in
humans. A subclass of the 2-OG oxygenase family is defined
by the presence of the jumonji C domain and members of this
subclass catalyze the oxidative demethylation of mono-, di-,
and trimethylated lysine residues located in histone proteins.
Another subclass of this family resembles the AlkB demethylase
of E. coli. Eight members of this subclass have been identified in
humans, with activities that include the dealkylation and oxida-
tive demethylation of modified bases in both DNA and RNA.
PCBPs may act as iron chaperones for the diiron monooxyge-
nases as well as the 2-OG-dependent dioxygenases and repre-
sent the major distributors of iron for the metallation of cytosolic
nonheme iron enzymes. The mechanism by which PCBPs
acquire cytosolic iron is unknown. In yeast, cytosolic monothiol
glutaredoxins are required to make iron available to iron-
requiring enzymes (Mu¨hlenhoff et al., 2010). Whether PCBPs
interact with these glutaredoxins awaits further study.EXPERIMENTAL PROCEDURES
Cell Culture
Huh7, A549, HEK293, and HEK293T cells were grown in high glucose
Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum, penicillin
G, 50 U/ml, and streptomycin, 50 mg/ml (Gibco-BRL).Cell MProtein Depletion by siRNA
PCBP1 and 2 were depleted using Stealth Select RNAi (Invitrogen, sequences
in Table S1). A nontargeting, scrambled sequence siRNA pool was used as
a control. Cells were transfected with 50 pmol of siRNA and harvested at
3 days after transfection. For some experiments, two sequential transfections
spaced 24 hr apart were performed.
RNA Extraction and RT PCR
RNA was isolated from cells using the RNeasy RNA Isolation kit (QIAGEN). For
reverse transcription, 1 mg of total RNAwas used in a reaction mixture contain-
ing dNTPs and superscript II (Invitrogen). Reverse transcriptionwas performed
for 10 min at 25C, 60 min at 42C, and 5 min at 70C. Quantitative real-time
PCR was performed using SYBR Green on an ABI 7500 system according
to the manufacturer’s protocols (primers in Table S2). The HIF1a, FIH1, and
PHD2 values were normalized to b-actin according to Pfaffl’s mathematical
model for relative quantification in real-time PCR (Pfaffl, 2001). Actin quantita-
tion did not vary with siRNA or DFO treatment.
Immunoblot Analysis
Nuclear and cytoplasmic extracts were prepared using a nuclear extract kit
(Active Motif). Nuclear extracts were used for HIF and CREB western blots.
Membranes were probed using mouse anti-HIF1a (Transduction, 1:1000) or
mouse anti-CREB (Cell Signaling, 1:1000) antibodies. For detection of hydrox-
ylated HIF1a, A549 cells were treated with 100 mM MG132 for 6 hr followed
by 25 mMDFO for 2 hr. Nuclear extracts (40 mg) were analyzed by western blot-
ting with a rabbit antibody that specifically recognizes HIF1m hydroxylation at
proline 564 (gift of O. Aprelikova). Whole-cell lysates or cytoplasmic extracts
were used for all other western blotting experiments. Whole-cell extracts
were prepared by lysis with buffer A (25 mM Tris [pH 8]; 40 mM KCl; 1% Non-
idet P40; 0.1% Triton; 1 mM DTT; 13 protease inhibitor cocktail, Roche).
Membranes were incubated with the indicated primary antibodies, followed
by detection with horseradish peroxidase-linked secondary antibodies (Amer-
sham) and enhanced chemiluminescence substrates (Pierce). Antibodies used
for western blotting were rabbit anti-PHD2 and anti-FIH1 (Novus Biologicals),
mouse anti-PCBP2 (Novus Biologicals), mouse anti-HA (Covance), and horse-
radish peroxidase-conjugated, mouse anti-FLAG (Sigma). Antibody against
recombinant human PCBP1 (Shi et al., 2008) was raised in chickens and puri-
fied from yolks by the manufacturer (Covance) and used at 1:2000–1:5000.
Western blots were quantitated using ImageJ.
Luciferase Activity Assays
HeLa 3XHRE Luc cells (Tian et al., 1997) were cultured and PCBP1 and/or
PCBP2 were depleted as described above. Firefly luciferase activity was
assayed using Dual-Luciferase reporter system (Promega). Samples were
read in Lumat LB 9507 luminometer (Berthold Technologies). For FIH activity,
PCBPs were depleted in HEK293 cells, then plasmids encoding the GalDBD/
HIF2a CADs, G5E1b-Luc reporter, pcDNA3.1-FIH1-myc-HisA, and pRL-TK
(Lando et al., 2002b) were transfected for 18 hr prior to measurement of
luciferase activity. Activity was reported as the ratio to renilla luciferase
control.
HIF Half-Life Determination
Huh7 cells depleted of PCBP1 and 2 were treated with 25 mM DFO for 2 hr.
Cycloheximide was added at 60 mg/ml, and the cells were collected at inter-
vals. HIF1a was analyzed in nuclear extracts.
VHL Capture Assay
HEK293T cells were depleted of PCBP1 and 2, treatedwith 25 mMDFO for 2 hr,
then lysed by sonication. HA-pVHL was synthesized by in vitro transcription/
translation reactions using TNT T7 Quick Coupled Rabbit Reticulocyte Lysate
kit (Promega). The VHL capture assaywas performed as described (Aprelikova
et al., 2009; Tuckerman et al., 2004) in buffer containing 2-OG, ascorbate, and
FeCl2.
PHD2 Assays
Biotinylated peptides derived from the HIF1a oxygen-dependent degra-
dation domain (Biotin-Acp-DLDLEALAPYIPADDDFQL or a hydroxylated
control Biotin-Acp-DLDLEALAP[OH]YIPADDDFQL) were immobilized onetabolism 14, 647–657, November 2, 2011 ª2011 Elsevier Inc. 655
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PCBP1 Delivers Iron to the HIF Prolyl Hydroxylase PHD2NeutrAvidin-coated 96-well plates. A549 cells were depleted of PCBP1 and/or
2, then harvested and resuspended in 1 ml hypotonic buffer (20 mM HEPES,
5mMNaF, 10 mMNa2MoO4 or Na3VO4, 0.1mMEDTA, protease inhibitor cock-
tail, and 2 mM DTT) for 15–20 min, then 0.5% NP-40 was added, and the
samples were vortexed for 10 s. Clarified lysates (50 mg/well) were incubated
in reaction buffer containing 20 mM Tris-Cl (pH 7.5), 5 mMKCl, 1.5 mMMgCl2,
2 mM DTT, 0–100 mM ferrous sulfate, 0.5 mM 2-OG and 1 mM ascorbate for
45 min at room temperature. Purified recombinant PCBP1 or albumin
(30 mM) was loaded with 100 mM ferrous sulfate for 2 hr at 4C in an anoxic
chamber (Coy Laboratory Products), then added to lysates at a final concen-
tration of 3 mM protein/10 mM Fe(II). Peptide hydroxylation was detected using
a polyclonal rabbit antibody raised against a hydroxylated HIF peptide, fol-
lowed by addition of a goat anti-rabbit HRP-conjugated secondary antibody
(Santa Cruz). Luminescence was measured in an EnVision plate reader
(PerkinElmer).
Protein Purification
Human PCBP1 was cloned into a pCDF-sumo fusion construct vector
(courtesy of Zhe Yang) and transformed into BL21* Escherichia coli competent
cells containing streptomycin resistance. Cells were grown in LB media at
37C to an OD600 of 0.6, induced with a IPTG concentration of 0.1 mM and
then grown for 22 hr at 15C. Cells were collected, resuspended in 30 ml of
buffer A (20 mM Tris [pH 7.9], 250 mM NaCl, 30 mM imidazole, 20% glycerol,
and 2.5 mM TCEP) with an EDTA-free protease inhibitor cocktail tablet
(Roche), 30 mgs of lysozyme, and were broken using a French Press. The
extract was spun at 21,000 rpm for 30 min and loaded on a nickel column.
Separation was carried out using a gradient between buffer A and buffer B
(20mM Tris [pH 7.9], 250 mM NaCl, 500 mM imidazole, 20% glycerol,
2.5 mM TCEP), with the protein eluting at 110–230 mM imidazole. The sumo
tag was cleaved by adding 1/1000 concentration sumo protease and incu-
bating overnight at 4C. Protein was buffer exchanged with buffer A before
passing on the nickel column again to separate the tag from the untagged
protein. The protein was run on a S-200 gel filtration column (GE Healthcare)
eluting at a molecular weight of 75 kDa, consistent with a protein as a dimer.
Immunoprecipitation
HEK293T cells were depleted of PCBPs, transiently transfected with
p3xFLAG-CMV-PHD2 (1 mg), then labeled overnight with 2 mM of 55Fe(II):NTA
(1:4 molar ratio). The cells were lysed in 50 mM Tris-HCl, (pH 7.5); 150 mM
NaCl; 0.5% NP-40; and protease (Sigma) and phosphatase inhibitors (Pierce).
PHD2 was immunoprecipitated with anti-FLAG antibody and protein A dyna-
beads (Invitrogen). IPs from mock-transfected cells were used to measure
nonspecific 55Fe background. Beads were washed, and retained 55Fe was
measured by scintillation counting (LS 6500, Beckman Coulter). For coimmu-
noprecipitations, anti-PCBP1 antibody or bulk chicken IgY (Gallus Immuno-
tech) was coupled to magnetic M280 tosylactivated dynabeads (Invitrogen)
using 100 mg of antibody. Beads were then blocked in 0.5% BSA and washed
with PBS (pH 7.4) containing 0.1% BSA prior to use. Cells were treated 2 hr or
overnight with either 20 mM ferric chloride or 100 mMDFO. The cells were lysed
in buffer A and lysates (3 mg) were incubated with beads, washed, and the
immune complexes were analyzed by western blotting.
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